Spectrin is critical for integrating membrane and cytoskeletal domains in excitable and nonexcitable cells. The role of ␤2-spectrin for vertebrate function is illustrated by dysfunction of ␤2-spectrin-based pathways in disease. Recently, defects in ␤2-spectrin association with protein partner ankyrin-B were identified in congenital forms of human arrhythmia. However, the role of ␤2-spectrin in common forms of acquired heart failure and arrhythmia is unknown. We report that ␤2-spectrin protein levels are significantly altered in human cardiovascular disease as well as in large and small animal cardiovascular disease models. Specifically, ␤2-spectrin levels were decreased in atrial samples of patients with atrial fibrillation compared with tissue from patients in sinus rhythm. Furthermore, compared with left ventricular samples from nonfailing hearts, ␤2-spectrin levels were significantly decreased in left ventricle of ischemic-and nonischemic heart failure patients. Left ventricle samples of canine and murine heart failure models confirm reduced ␤2-spectrin protein levels. Mechanistically, we identify that ␤ 2-spectrin levels are tightly regulated by posttranslational mechanisms, namely Ca 2ϩ -and calpain-dependent proteases. Furthermore, consistent with this data, we observed Ca 2ϩ -and calpain-dependent loss of ␤ 2-spectrin downstream effector proteins, including ankyrin-B in heart. In summary, our findings illustrate that ␤ 2-spectrin and downstream molecules are regulated in multiple forms of cardiovascular disease via Ca 2ϩ -and calpain-dependent proteolysis.
5 ␤-spectrin genes) linked with actin. Furthermore, through direct interactions with ankyrin family proteins, spectrins integrate the cytoskeleton with a host of membrane ion channels, transporters, and cell adhesion molecules (5, 13, 14) . In humans, spectrin gene variants are linked with hereditary spherocytosis (2) and spinocerebellar ataxia (32) . In mice, spectrin deficiency is associated with progressive hindlimb paralysis, deafness, and tremor (54) . Finally, spectrin-associated ankyrin molecules are linked with a host of phenotypes in humans and animals, including spherocytosis (2), ataxia (70) , bipolar disorder, diabetes (24, 36) , skeletal muscle disease (4) , and cardiovascular disease (12, 62) .
While spectrins have been extensively studied in congenital forms of disease, we know little regarding their roles or regulation in more common forms of acquired disease, particularly in heart failure and arrhythmia. In heart, there are two primary ␤-spectrin gene products (␤ 2 -spectrin and ␤ IV spectrin). While ␤ IV spectrin function has been extensively examined over the past 5 yr (19, 29 -31, 38, 44) , we still know little regarding the potential functions of ␤ 2 -spectrin in cardiac function, and essentially nothing is known regarding ␤ 2 -spectrin function in common forms of cardiovascular disease.
We recently identified ␤ 2 -spectrin as a nodal protein required for the biogenesis and maintenance of the cardiomyocyte submembrane cytoskeleton (62) . Mice deficient for cardiac ␤ 2 -spectrin display defects in membrane and sarcoplasmic reticulum (SR) ion channel and transporter targeting as well as cytoskeletal organization (62) . Furthermore, mice selectively lacking ␤ 2 -spectrin in heart ["␤ 2 -spectrin conditional knockout (cKO) mice"] show severe myocyte electrical phenotypes and arrhythmias (62) . Finally, human gene variants that alter ␤ 2 -spectrin/ankyrin-B interactions are associated with arrhythmia (62) . As a first step in defining the regulation of ␤ 2 -spectrin in common forms of cardiovascular disease, we analyzed ␤ 2 -spectrin regulation in acquired human cardiovascular disease as well as animal heart failure and arrhythmia models. ␤ 2 -Spectrin levels were reduced in disparate forms of human cardiovascular disease, including atrial fibrillation and ischemic and nonischemic heart failure. Furthermore, ␤ 2 -spectrin levels were reduced in large and small animal models of cardiovascular disease, including canine nonischemic heart failure and murine pressure overload-induced heart failure. Mechanistically, in line with data in other organs, we deter-mined that ␤ 2 -spectrin levels are tightly regulated by posttranslational mechanisms, namely Ca 2ϩ -dependent calpain proteases. In fact, we discovered that Ca 2ϩ -and calpain-dependent regulation of ␤ 2 -spectrin alters downstream binding partners, including ankyrin-B. In summary, our findings illustrate that ␤ 2 -spectrin and downstream molecules are highly regulated in multiple forms of cardiovascular disease through mechanisms that include Ca 2ϩ -and calpain-dependent proteolysis.
MATERIALS AND METHODS

Animals.
All experiments were performed in age-matched (2-4 mo) littermates (56) . All animal procedures were approved and were in accordance with institutional guidelines (Institutional Animal Care and Use Committee; Ohio State University).
Statistics. P values were determined with the unpaired Student's t-test (2-tailed) for single comparisons. Multiple comparisons were analyzed by use of ANOVA. The Bonferroni test was used for post hoc testing. Data were all normally distributed by Shapiro-Wilk test and are presented as means Ϯ SE. If the data distribution failed normality tests with the Shapiro-Wilk test, rank-based ANOVA and the Dunn multiple-comparisons test were performed.
Canine heart failure. All canine procedures were approved by the Ohio State University Institutional Animal Care and Use Committee (primary investigator Carnes) and conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Before studies, dogs were verified to have normal cardiac function by routine electrocardiograms and echocardiographic examinations during butorphanol tartrate (0.5 mg/kg im) sedation. Dogs had a right ventricle (RV) pacemaker lead implanted in the RV apex, and heart failure was induced by tachypacing for 4 mo as previously described (63) . To assess time dependence during the progression of heart failure, echocardiograms and electrocardiogram were measured at baseline, after 1 mo, and 4 mo of pacing in the 4-mo heart failure group. A second group of dogs was RV tachypaced for 1 mo at 180 beats/min, and echocardiograms were measured at baseline and at the end of the pacing protocol as previously reported (52, 53 ). An age-matched group of healthy dogs was used as controls and studied in parallel. Functional parameters of canines are noted (43) . Following experiments, tissue samples were snap-frozen and stored at Ϫ80°C.
Human tissue. For atrial tissue, experimental protocols were approved by the ethics committee of the Medical Faculty Mannheim, University of Heidelberg (no. 2011-216N-MA). Each patient provided written informed consent. During routine cannulation procedures in patients undergoing open-heart surgery for cardiac bypass grafting and valve replacement, the tip of the right atrial appendage was removed and immediately snap-frozen in liquid nitrogen. Appendages were obtained from 12 sinus rhythm and 10 paroxysmal atrial fibrillation patients. The atrial fibrillation group included patients in sinus rhythm at surgery with a history of at least one episode of selfterminating atrial fibrillation lasting Ͻ7 days (paroxysmal atrial fibrillation).
For human heart failure samples, left ventricular (LV) tissue was obtained from explanted hearts of patients undergoing heart transplantation at The Ohio State University. Approval for use of human subjects was obtained from the Institutional Review Board of Ohio State University. LV tissue from healthy donor hearts not suitable for transplantation (subclinical atherosclerosis, age, no matching recipients) was obtained through Lifeline of Ohio. The investigation conforms to the principles outlined in the Declaration of Helsinki. As noted (9) , samples included the following: nonischemic heart failure: n ϭ 7 (4 male/3 female), age ϭ 52 Ϯ 13 yr, and LV ejection fraction of 14.5 Ϯ 5.2%; nonfailing controls: n ϭ 5 (2 male/3 female), age ϭ 47 Ϯ 12 yr. Ischemic heart failures samples were defined as the presence of any epicardial coronary vessels with Ն75% stenosis or any history of myocardial infarction or coronary revascularization (either percutaneous transluminal coronary angioplasty or coronary artery bypass grafting) (16) .
Immunoblots. Tissue was harvested and immediately placed in ice-cold homogenization buffer (in mM: 25 Tris·HCl, 150 NaCl, 1 EDTA; supplemented with 1:1,000 protease inhibitor cocktail and 1% Nonidet P-40) (51) . Following bicinchoninic acid assay (BCA) quantitation, tissue lysates were electrophoresed using the Mini-PROTEAN tetra cell (Bio-Rad) and a 4 -15% precast TGX gel (Bio-Rad). Gels were transferred to a nitrocellulose membrane using the Mini-PROTEAN tetra cell (Bio-Rad) and blocked for 1 h at room temperature. Primary antibody incubation was carried out overnight at 4°C. Densitometric analyses were performed using ImageLab software (Bio-Rad). For all experiments, protein values were normalized against an internal loading control validated against the specific pathology. With the exception of human atrial fibrillation samples that use calsequestrin as the standard loading control (11, 12, 66) , GAPDH was used. Dominant high-molecular-mass bands (Ͼ220 kDa) were quantified in each sample to avoid potential bias toward quantification of low-molecularmass degradation products.
Antibodies. Antibodies used were mouse monoclonal anti-Na ϩ / Ca 2ϩ exchanger-1 (R3F1; Swant), ankyrin-B (36), Ca 2ϩ /calmodulindependent protein kinase (CaMK) II␦ pT287 (Badrilla), anti-voltagegated Ca 2ϩ channel 1.2 (Affinity Bioreagents), ␣-actinin (Sigma), ␤2-spectrin (Abcam), GAPDH (Fitzgerald), ryanodine receptor 2 (Abcam), and sarcoendoplasmic reticulum 2 (Affinity Bioreagents).
Transverse aortic constriction. Transverse aortic constriction (TAC) was performed as described (23) . Briefly, mice were anesthetized (100 mg/kg ip ketamine ϩ 5 mg/kg xylazine), intubated, and placed on a respirator (120 breaths/min, 0.1 ml tidal volume). Anesthesia was monitored by repeated hindlimb response to pinch. Aorta was exposed via a midline sternotomy. A 6.0 Prolene suture was placed around the aorta distal to the brachiocephalic artery. The suture was tightened around a blunted 27-gauge needle placed next to the aorta. The needle was removed, and the chest was closed. Echocardiography was performed at regular intervals for 2 mo to assess cardiac function. With our laboratory protocol, this protocol produces decreased ejection fraction and increased heart-to-body weight ratio compared with sham mice (23) . Age-matched littermates were used as sham-operated controls. Hearts were harvested from dead mice (2% Avertin, 20 l/g ip) via rapid thoracotomy. Adequate anesthesia was monitored via pain response to hindlimb toe pinch.
Echocardiography. Eight-week-old male C57/BL6 mice weighing Ͼ20 g were used for these experiments. Digital images were obtained at a frame rate of 180 images/s. Transthoracic echocardiogram was performed using the Vevo 2100 (Visualsonics). The mice were anesthetized using 2.0% isoflurane in 95% O2-5% CO2 at a rate of ϳ0.8 l/min. Anesthesia was maintained by administration of oxygen and ϳ1% isoflurane. Electrode gel was placed on the ECG sensors of the heated platform, and the mouse was placed supine on the platform to monitor electrical activity of the heart. A temperature probe was inserted in the rectum of the mouse to monitor core temperature of ϳ37°C. The MS-400 transducer was used to collect the contractile parameters of the heart in the short-axis M-mode. LV wall thickness Proteolysis experiments. Ca 2ϩ and calpain proteolysis experiments were performed on mouse heart and whole brain tissues as adapted from Ref. 59 . Wild-type mouse heart and brain homogenates were prepared from freshly dissected tissues. Samples were homogenized in homogenization buffer (10 mM Tris·HCl and 0.32 M sucrose). Tissues were centrifuged at 4°C at 600 revolutions/min for 10 min, and the supernatant was quantitated by BCA (ThermoScientific).
Supernatants were diluted with homogenization buffer to a concentration of 6.0 mg/ml. Lysate (45 l) was added to 45 l cleavage buffer (40 mM Tris·HCl, 50 mM NaCl, 2 mM DTT; final concentration in reaction: 20 mM Tris·HCl, 50 mM NaCl, 1 mM DTT) with varying concentrations of CaCl 2 (0, 1, or 10 mM CaCl2; final CaCl2 concentrations 0, 0.5, and 5 mM). Samples that used MDL-28170 were preincubated with 100 M MDL-28170 (made in 100% DMSO; Sigma) for 2 min at room temperature before addition of cleavage buffer. Samples were incubated at 37°C for 30 min, and the reactions were stopped with 100 l Laemmli ϩ ␤-mercaptoethanol (19:1 dilution). Sample (30 l) was separated on 4 -15% Tris glycine gels, and proteins were transferred to nitrocellulose. Blots were incubated with anti-ankyrin-B, anti-␤ 2-spectrin (Abcam), and anti-GAPDH (Fitzgerald) in 5% nonfat dry milk/Tween 20-Tris-buffered saline (TTBS) overnight at 4°C, followed by three washes in TTBS. Following incubation in secondary antibody (donkey antimouse, donkey antirabbit; Jackson Laboratories) for 2 h at 4°C, blots were washed in TTBS and developed using a Bio-Rad Clarity ECL kit.
RESULTS
␤ 2 -Spectrin is expressed in human and mouse heart. As a first step to investigate the role of ␤ 2 -spectrin in human cardiovascular function, we evaluated the chamber-specific expression of ␤ 2 -spectrin protein in nonfailing human heart. We observed ␤ 2 -spectrin in all four chambers of nonfailing human heart, although levels were significantly reduced in atria compared with ventricle (n ϭ 4, P Ͻ 0.05; Fig. 1, A and B) . In mice, ␤ 2 -spectrin was expressed in all four cardiac chambers. ␤ 2 -Spectrin protein levels were similar between right and left atria but significantly reduced in RV of mouse heart compared with LV (n ϭ 4, P Ͻ 0.05; Fig. 1, C and D) . In summary, ␤ 2 -spectrin is expressed in all four chambers of nonfailing human and mouse heart, with species-specific differences in relative chamber protein expression.
␤ 2 -Spectrin levels are reduced in human atrial fibrillation. We recently linked dysfunction in the ␤ 2 -spectrin-ankyrin-B pathway with congenital human arrhythmia (62) . Furthermore, ankyrin-B loss-of-function mutations cause human atrial fibrillation (12) , and ankyrin-B protein levels are reduced in atrial samples of patients with atrial fibrillation (12) . Because ankyrin-B requires ␤ 2 -spectrin for cellular targeting and stability (62), we investigated whether loss of ␤ 2 -spectrin may potentially occur upstream of reduced ankyrin-B levels in atrial fibrillation. We examined the expression of ␤ 2 -spectrin protein in right atrial tissue from patients with normal sinus rhythm vs. patients with paroxysmal atrial fibrillation. Tissue of patients with documented paroxysmal atrial fibrillation displayed significant reduction in ␤ 2 -spectrin protein levels compared with samples from individuals in normal sinus rhythm (n ϭ 12 patients in sinus rhythm; n ϭ 10 patients with paroxysmal atrial fibrillation; P Ͻ 0.05; Fig. 2 ). We observed no change in the expression of calsequestrin 2, a standard loading control not altered in atrial fibrillation (10, 12, 66) . In summary, ␤ 2 -spectrin protein levels are significantly reduced in right Fig. 1 . ␤2-Spectrin protein expression in human and mouse cardiac chambers. A and B: ␤2-spectrin protein levels in heart chambers from nonfailing human heart (n ϭ 4 samples/chamber, *P Ͻ 0.05). C and D: ␤2-spectrin protein levels in heart chambers from wild-type mouse (n ϭ 4 samples/chamber, *P Ͻ 0.05). LV, left ventricle; RV, right ventricle; LA, left atrium; RA, right atrium. Fig. 2 . ␤2-Spectrin levels are reduced in human atrial fibrillation. B: atrial samples of patients with documented paroxysmal atrial fibrillation (pAF, n ϭ 10) display reduced ␤2-spectrin protein expression compared with individuals in normal sinus rhythm (SR, n ϭ 12; *P Ͻ 0.05). A: calsequestrin was used as a loading control.
atrial samples of patients with acquired forms of human atrial fibrillation. This loss provides a potential rationale for reduced ankyrin-B expression in human atrial fibrillation (12) .
␤ 2 -Spectrin protein levels are altered in human heart failure. To evaluate a broader role for ␤ 2 -spectrin in common forms of cardiovascular disease arrhythmia, we next evaluated ␤ 2 -spectrin protein levels in LV lysates of patients with nonischemic heart failure compared with lysates from nonfailing hearts. We observed a significant reduction in ␤ 2 -spectrin protein levels in LV samples from patients with documented nonischemic heart failure vs. nonfailing heart samples (P Ͻ 0.05; Fig. 3B ). Activated CaMKII␦ was used as a control for the heart failure phenotype (35, 38, 46) (n ϭ 5 nonfailing; n ϭ 5 nonischemic heart failure; P Ͻ 0.05; Fig. 3D ). Consistent with loss of ␤ 2 -spectrin in human nonischemic heart failure samples, we observed a significant reduction in ankyrin-B protein expression compared with nonfailing human hearts (n ϭ 5 nonfailing; n ϭ 5 nonischemic heart failure; P Ͻ 0.05; Fig. 3J ). Notably, while we observed a significant decrease in ␤ 2 -spectrin protein levels in samples from human nonischemic heart failure ( Fig. 3B) , ␤ 2 -spectrin transcript levels were not significantly different between nonfailing and nonischemic heart failure samples [n ϭ 3/group; P ϭ not significant (NS)]. Thus, ␤ 2 -spectrin protein expression is likely reduced in nonischemic heart failure samples by posttranscriptional mechanisms.
We next evaluated ␤ 2 -spectrin protein levels in LV lysates of patients with ischemic heart failure compared with lysates from nonfailing hearts. Consistent with findings from nonischemic heart failure samples, we observed a significant decrease in ␤ 2 -spectrin protein levels in all samples (n ϭ 5 nonfailing; n ϭ 5 failing; P Ͻ 0.05; Fig. 3M ).
␤ 2 -Spectrin protein levels are reduced in small and large animal models of heart failure. ␤ 2 -Spectrin levels are reduced in human heart failure. However, molecular mechanisms underlying heart disease may differ between human and animal disease models, as well as between large and small animal models. We therefore examined ␤ 2 -spectrin protein expression in large and small animal models of heart failure. We first performed analysis of ␤ 2 -spectrin levels in LV samples isolated from mice following 6 wk of transaortic constriction [TAC; ejection fraction reduced ϳ50% (23)]. This well-characterized disease model provides the ability to assess phenotypes in a nonischemic model of heart failure, including alterations in signaling pathways activated by mechanical stretch (45, 58) . Consistent with our findings in human nonischemic heart failure, LV samples from TAC mice displayed a significant decrease in ␤ 2 -spectrin protein expression (n ϭ 4/group; P Ͻ 0.05; Fig. 4 , A and B) compared with sham control animals. Together, ␤ 2 -spectrin protein levels are consistently decreased in human heart failure as well as large and small animal models of heart failure.
While small animal rodent models have been widely used to study the molecular mechanisms underlying cardiac disease pathogenesis, there are inherent differences in cardiac physiology between mice and humans (e.g., heart rate, metabolism, and heart size). We therefore used a large animal preclinical model of nonischemic heart failure. This specific canine disease model is valuable as the chronic tachypacing-induced cardiomyopathy for several reasons: 1) it is nonischemic in nature, 2) it does not require significant structural or exogenous hormonal stresses on the heart, and 3) it displays a remodeling process that takes place over a more extended time frame (1-4 mo) compared with most animal disease models (3, 43, 64) . Thus, this model provides the ability to assess ␤ 2 -spectrin regulation in response to long-term nonischemic stress. Similar to human data, we observed a significant decrease in ␤ 2 -spectrin protein expression in LV samples from this canine model of heart failure (3, 43) compared with nonfailing control hearts at both 1 and 4 mo (n ϭ 4/group; P Ͻ 0.05; Fig. 4, C and  D) . In summary, both small and large animal models of heart failure showed significant alterations in ␤ 2 -spectrin levels, suggesting a potential common upstream pathway for protein regulation.
␤ 2 -Spectrin protein levels are regulated by Ca 2ϩ and calpain. In other organs, degradation of the spectrin-based cytoskeleton is linked with cellular remodeling (8, 49, 69) . Furthermore, this remodeling is tightly linked with cleavage of the spectrin-based cytoskeleton by Ca 2ϩ -dependent calpain proteases (18, 42, 61) . Heart failure is characterized by alterations in cardiac Ca 2ϩ handling and elevated reactive oxygen species, both known to activate cardiac calpain proteases (48, 67) . We therefore examined the impact of altered Ca 2ϩ -mediated proteolysis on ␤ 2 -spectrin protein expression. Tissue preparations from adult mouse hearts (or brain as positive control) were analyzed after 30 min of exposure to pathological Ca 2ϩ concentrations to activate calpain proteases. In response to elevations in Ca 2ϩ , ␤ 2 -spectrin protein levels in both brain and heart lysates were significantly reduced compared with control samples (P Ͻ 0.05; Fig. 5 ) (35) . The selectivity of Ca 2ϩ -dependent activation of calpain in ␤ 2 -spectrin degradation was evaluated in proteolysis experiments Ϯ calpain inhibitor MDL-28170 (35) . In both heart and brain lysates the Ca 2ϩ -dependent degradation of ␤ 2 -spectrin was blocked by MDL-28170 (Fig. 5) . We observed similar results for the ␤ 2 -spectrin downstream partner ankyrin-B in both heart and brain (Fig. 5) . Thus, ␤ 2 -spectrin levels are tightly regulated by local cellular Ca 2ϩ concentrations through activation of calpain. Furthermore, these data provide a logical explanation for reduced ␤ 2 -spectrin and ankyrin-B protein levels in pathophysiological conditions where Ca 2ϩ levels are increased (12, 35, 68) .
DISCUSSION
Dilated cardiomyopathies, heart failure, and arrhythmias are a significant health burden (20, 50) . Despite improving medical therapies, cardiac resynchronization therapies, and LV assist devices (1), heart failure remains a global epidemic. The lifetime risk of developing heart failure is 20% (41) with a 5-yr age-adjusted mortality at 59 and 45% for men and women, respectively (39) . Furthermore, the global burden of the most common arrhythmia, atrial fibrillation, continues to increase and have untoward effects on patients (17, 68) . Thus, the identification of pathways underlying the development and progression of heart failure and arrhythmias is essential for the creation of new diagnostics and treatments.
Emerging data have emphasized the role of cytoskeletal protein modulation in the progression of heart failure (25-28), but as a whole the role of the myocyte cytoskeleton has remained relatively understudied compared with its membrane protein partners (e.g., ion channels, receptors). Our findings provide data regarding the regulation of ␤ 2 -spectrin protein expression in both structural and electrical heart disease, specifically demonstrating significant reductions in ␤ 2 -spectrin expression in ischemic and nonischemic heart failure and atrial fibrillation. Mechanistically, alterations in cellular Ca 2ϩ induce loss of ␤ 2 -spectrin levels in heart via proteolytic cleavage by calpains. Our findings illustrate significant remodeling in animal and human disease that underlies several classes of cytoskeletal and membrane protein reorganization in heart failure. Our data demonstrate that ␤ 2 -spectrin is a key component of this cytoskeletal network, and lack of spectrin in heart leads to Fig. 3 . ␤2-Spectrin protein levels are reduced in human heart failure samples. A and B: ␤2-spectrin protein expression was significantly decreased in LV samples from human nonischemic heart failure (NIHF) compared with nonfailing (NF) human LV heart samples (n ϭ 5 NF, n ϭ 5 NIHF; *P Ͻ 0.05). C-J: cardiac protein expression in human NIHF. In line with prior studies, compared with LV samples from NF hearts, LV samples from patients with documented NIHF displayed a significant reduction in ankyrin-B protein expression while showing a significant increase in Ca 2ϩ /calmodulin-dependent protein kinase (CaMK) II␦ pT287 expression (*P Ͻ 0.05). K and L: ␤2-spectrin protein levels are reduced in human ischemic heart failure (IHF) samples. ␤2-Spectrin protein expression was significantly decreased in LV samples from patients with ischemic heart failure compared with NF human LV heart samples (n ϭ 5 NF, n ϭ 5 IHF; *P Ͻ 0.05).
adverse remodeling in mice, culminating in a heart failure phenotype susceptible to arrhythmias and eventual death (62) . Notably, humans with gene variants that block interactions between ␤ 2 -spectrin and ankyrin-B display arrhythmia phenotypes (62) .
An important finding of this study is the link of ␤ 2 -spectrin with the development of heart failure. Our laboratory previously demonstrated that, following acute insult or chronic injury, ankyrin-B is posttranslationally degraded by oxidative stress and/or increased Ca 2ϩ . Furthermore, these phenotypes are blocked by the calpain inhibitor MDL-28170 (35) . Our new findings and the work of other groups in noncardiac systems support upstream degradation of ␤ 2 -spectrin by Ca 2ϩ -dependent calpain proteases as the source of this degradation and subsequent cytoskeletal/membrane remodeling. The selective and rapid degradation of spectrins via distinct intracellular pathways was first demonstrated using chicken erythrocytes (69) . Later it was demonstrated that an influx of Ca 2ϩ leads to rapid cleavage of ␤ 2 -spectrin, and in brain prominent calpain cleavage products appear at 166 and 120 kDa (18) . In our studies, while we observed parallel changes in ankyrin-B with ␤ 2 -spectrin in heart, we did not observe altered expression levels of Na ϩ /Ca 2ϩ exchanger. This observation may be due to the known presence of ankyrin-dependent and ankyrin-inde- Fig. 4 . ␤2-Spectrin protein expression in canine and mouse models of heart failure. A and B: LV samples isolated from mice following 6 wk of transaortic constriction (TAC) displayed a significant decrease in ␤2-spectrin protein expression compared with samples from sham control (wild-type) mice (n ϭ 4 sham, n ϭ 4 TAC; *P Ͻ 0.05). C and D: ␤2-spectrin protein levels are significantly reduced in LV samples of a chronic canine heart failure model at 1 and 4 mo compared with control heart samples (n ϭ 4 control, n ϭ 4 heart failure at 1 or 4 mo; *P Ͻ 0.05). Finally, based on known protein partners, it is exciting to speculate on new nonstructural roles for ␤ 2 -spectrin in cardiovascular physiology. ␤ 2 -Spectrin has key roles in cardiogenesis, and global loss of ␤ 2 -spectrin results in defects in heart development linked with defects in TGF-␤ signaling (40) (involved in translocation of Smad3 and Smad4) (65) . Furthermore, the ␤ 2 -spectrin partner ␣-spectrin is known to have multiple roles in organizing Mena/vasodilator-stimulated phosphoprotein targeting and thus regulation of actin assembly/ dynamics (6) . Furthermore, ␣-spectrin displays its own E2/E3 ubiquitin-conjugating/-ligating enzymatic activity (22, 34) . Thus, it will be important for future experiments to integrate both signaling and structural analysis to define the diversity of ␤ 2 -spectrin functions at both baseline and in disease.
Significance. Our findings support significant remodeling of cellular cytoskeleton in various disease states. The spectrin pathway is emerging as a new target for therapeutic interventions, and there are early data that suggest that spectrin breakdown products could serve as biomarkers for disease severity and prognosis. Recent data suggest that calpain-2 activation degrades ␤ 2 -spectrin into four major fragments (110, 108, 85, and 80 kDa) in rat brain after injury (37) . In fact, based on this disease pathway, spectrin degradation products have been proposed as early markers for tissue and organ damage (33, 37, 57, 60) . Based on our data and these findings in brain (33, 60) , it is exciting to speculate that ␤ 2 -spectrin breakdown products may serve as an early diagnostic marker for cardiovascular phenotypes, including myocardial infarction, acute heart failure, or ventricular arrhythmia.
Study limitations. While a number of findings in our study are descriptive, the findings provide potential new methods to assess both acute and chronic cardiovascular damage, as well as complement small rodent studies performed using ␤ 2 -spectrin cKO mice (62) . However, it is important to note that the downstream pathways observed in ␤ 2 -spectrin cKO mice (62) and ␤ 2 -spectrin global null mice [both with complete loss of ␤ 2 -spectrin (40)] likely differ from those observed in acquired forms of cardiovascular disease (reduced only partially across disease pathologies). In fact, an important finding from this study is the consistent loss of ␤ 2 -spectrin expression across diverse etiologies. These findings may represent compensatory remodeling in these pathologies. Alternatively, these findings may support multiple populations of ␤ 2 -spectrin (calpain sensitive vs. calpain resistant) in the myocyte. While our findings are consistent with data in other organ systems, an important future study may be to perform similar experiments in the presence of in vivo calpain inhibitors to analyze the potential preservation of spectrin levels following acute stress. Furthermore, as it appears that loss of ␤ 2 -spectrin has a role in congenital and acquired heart disease, it will be important to further define both up-and downstream molecular pathways. Finally, like ankyrins, spectrins are highly regulated in vivo, both by complex alternative splicing events and posttranslational modifications (7). Thus, while our findings support alterations in the dominant high-molecular-mass form(s) of ␤ 2 -spectrin, it will be critical for future studies to define the likely large spectrum of ␤ 2 -spectrin splice product in heart, as well as how each product is regulated at the organ, cell, and subcellular level. 
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